Roquefort Therapeutics Extends Long-Stop Date for AO-252 License Deal

08:43 AM EST, 12/12/2025 (MT Newswires) -- Roquefort Therapeutics (ROQ.L) said Friday the long-stop date for its exclusive license deal with Coiled Therapeutics and A2A Pharmaceuticals for cancer drug candidate AO-252 was extended to March 16, 2026, from Jan. 31, 2026. The extension, which was due in part to the impact of the holiday season, will allow more time for Roquefort's enlarged share capital to be admitted on London's AIM market, as well as to gather more clinical data from the ongoing early-stage study of AO-252 in solid tumors. As a result, certain commercial terms of the license deal were updated, including an increase in the upfront payment to 31.9 million pounds sterling from the prior 25.5 million pounds.